Clinical Trials

Quietmind Foundation is a leader in conducting integrative research on drug-free, noninvasive technologies and treatment methods for neurological and neuropsychiatric disorders, head trauma, and peak performance.

Clinical Trials

 

Quietmind Foundation’s research agenda is the repair, regrowth, and retraining of brain functions compromised by the full range of neuropsychiatric disorders, traumatic head injuries, and neurodegenerative disorders as well as the normal stressors of everyday life. Through our own cutting-edge research and our collaboration with colleagues around the world, we are inventing breakthrough therapeutic interventions for people struggling with Parkinson’s disease, dementia, ADD/ADHD, autism, anxiety, depression, addictions, post-concussion syndrome, PTSD, stroke, traumatic brain injury (TBI), epilepsy, and the cognitive side-effects of chemotherapy.

 

We are also focused on studying technologies that can assist already high-functioning children and adults achieve and maintain peak performance in artistic, athletic, academic, and professional endeavors. Results from over fifty years of ongoing research are constantly generating, reconfiguring, and shaping an informed baseline for ever-encompassing, proven applications for neurofeedback. These techniques allow a person to effortlessly open the mind’s “door” and enter the ‘‘zone,” raising the bar of self-actualized, permanent, mental and physical achievement.

 

  •     Anxiety and stress? Relieved
  •     Attention and focus? Heightened
  •     Perception and stamina? Enhanced
  •     Performance? Improved

 


 

Executives and human resource managers are using our research results to improve individual, team, and organizational performance issues including: conflict resolution, team selection and development, product marketing and placement, and executive development. 

 

Satellite Research Sites

Several QMF satellite research sites have also been established, funded, and maintained because of the ongoing support of local professionals and volunteers. QMF research staff provide professional overview, monitoring, and training. Participant testing, pre- and post-clinical trial, takes place regionally or in our QMF offices in Plymouth Meeting, PA. Potential participants who otherwise cannot afford or are too physically or mentally challenged to travel are now better able to participate in one of our ongoing clinical trials.

 

Call 610-940-0488 to locate or help create a remote clinical trial site in your area.

 

FAQ about clinical trials

 

What is a clinical trial?

A clinical trial is research using human volunteers to answer a specific health question. For example: “Does this new treatment help me remember things better?”

 

Why participate in a trial?

For eligible participants, a clinical trial can provide access to new treatments before they are commercially available while at the same time helping to advance medical knowledge.

 

Am I a candidate?

Each clinical trial includes specific inclusion criteria (factors that allow someone to participate) and exclusion criteria (factors that prevent someone from participating). The study coordinator can review the reasons why you may or may not be a good candidate for a particular study.

 

Call 610-940-0488 to learn more.

 

Active QMF Clinical Trials

Trial #1: Shine a Light on Alzheimer’s, Phase I.

This ongoing randomized, double-blind, placebo-controlled study is being conducted to determine whether 1072nm infrared light stimulation can slow and perhaps reverse the symptoms of early to mid-stage dementia. Accepted participants receive 28 consecutive days of twenty-minute sessions. Participants’ abilities are tested before and after the 28-day trial. Travel-related expenses are reimbursed up to $250.

If you or a loved one are suffering from early to mid-stage dementia, call 610-940-0488 to learn how to participate in this ongoing clinical trial.

If you or your physician would like to read or download the trial abstract, the exclusion criteria, the informed consent document, or other documents pertinent to this clinical trial: Click here.

 

Trial #2: EEG Biofeedback to treat executive symptoms of dementia, Phase II.

This Phase II study involves the use of EEG biofeedback training to relieve symptoms of dementia. Accepted subjects participate in 40 sessions of biofeedback conducted twice weekly, with neurophysiological and neuropsychological testing carried out before and after the 40-session period.

To determine your eligibility, call 610-940-0488.

 

Completed QMF Research Studies

Neurofeedback to treat ADHD & Conduct Disorder.

QMF studied the efficacy of neurofeedback with children in the public mental health system diagnosed with ADHD and conduct disorder. We showed that neurofeedback can be provided effectively in a community mental health and residential treatment context. Sponsored by Philadelphia Office of Mental Health/Mental Retardation.

 

Neurofeedback to treat Anxiety and Opiate Addiction.

QMF completed a pilot study on the effects of biofeedback on anxiety symptoms in a methadone-maintained population. Sponsored by Thomas Jefferson Medical College, Department of Psychiatry and Human Behavior.

 

Neurofeedback to treat Autistic Spectrum Disorder.

This study using neurofeedback on children with autistic disordered was carried out in a public charter school setting. Sponsored by the Philadelphia Academy Charter School.

 

Neurofeedback to treat Alzheimer’s Disease.

QMF studied the impact of EEG-driven stimulation biofeedback on the cognitive and behavioral symptoms of people struggling with early stage Alzheimer’s dementia.

Sponsored by the Helen Bader Foundation.


Neurofeedback to treat early to mid-stage Dementia, Phase I.

This first phase of a multiphase research project, studied the use of quantitative EEG(qEEG)-driven biofeedback training to reduce the symptoms of dementia and increase executive function. Subjects participated in 40 sessions of biofeedback training conducted twice weekly, with qEEG and neuropsychological testing conducted before and after the 40-session period. Results were presented at the 2009 International Conference on Alzheimer’s Disease (ICAD) in Vienna, Austria. Click here to download the poster

 

Sponsored by the Phoebe Haas Charitable Trusts.